Baseline characteristics of 915 patients with rheumatoid arthritis. Values are median (interquartile range) unless otherwise specified.
| Characteristics | Values |
|---|---|
| Female, % | 80.0 |
| Age, yrs | 59.3 (49.7–66.2) |
| Duration, yrs | 10.0 (6.0–16.0) |
| DAS28 | 2.1 (1.7–2.4) |
| CDAI | 1.8 (0.6–3.4) |
| SDAI | 1.9 (0.7–3.6) |
| Boolean trial remission, % | 51.4 |
| CDAI remission, % | 70.1 |
| Boolean practice remission, % | 53.4 |
| SDAI remission, % | 68.2 |
| J-HAQ score | 0.0 (0.0–0.4) |
| No. tender joints, out of 28 | 0 (0–0) |
| No. swollen joints, out of 28 | 0 (0–0) |
| Patient’s pain assessment, mm | 7 (1–16) |
| PtGA, mm | 8 (2–18) |
| PGA, mm | 3 (0–8) |
| CRP, mg/dl | 0.07 (0.03–0.21) |
| ESR, mm/h | 12.0 (7.5–18.0) |
| NSAID use, % | 52.9 |
| DMARD use, % | 93.3 |
| MTX use, % | 63.9 |
| MTX dose, mg/week | 7.5 (6.0–10.0) |
| Corticosteroid use, % | 40.2 |
| Corticosteroid dose, mg/day | 3.0 (2.0–5.0) |
| Biologics use, % | 4.9 |
DAS28: 28-joint Disease Activity Score; CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index; J-HAQ: Japanese version of the Health Assessment Questionnaire; PtGA: patient’s global assessment; PGA: physician’s global assessment; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate.